AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$RLAY

Patel Sanjiv sold $913K of RLAY

Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.94 ($0.91M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Patel Sanjiv
Published Sep 9, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLAY
Bearish
medium confidence
Mentioned
$RLAY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYBearishLow
01

Why it matters

The CEO's sale reduces his ownership, which some investors interpret as a negative signal, though the 10b5‑1 plan suggests pre‑planned execution.

02

Market read

Primary disclosure of an insider sell; modest relevance for traders monitoring biotech stocks.

03

What to watch

Potential upcoming clinical data releases could offset sell‑off sentiment.

Relevance 4/10Novelty 6/10Timing: post‑market on 2026‑09‑08

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$RLAYBearishMedium confidence
Context

CEO Sanjiv Patel sold 48,199 shares for $912,889 via a 10b5‑1 plan, reducing his stake to 519,500 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale is sizable for a mid‑cap biotech but below material‑scale thresholds; market may view it as a slight negative cue.

Market effects

Sector

May prompt scrutiny of other biotech insider transactions.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not indicative of outlook.

Key entities

  • Company
    Relay Therapeutics, Inc.

    Biopharma developing precision medicines.

  • Executive
    Sanjiv Patel

    President and CEO of Relay Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

AUG 6
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K6 min
JUN 2
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com1 min